GeneDx Holdings Corp. reported significant financial growth in its latest 10-K filing for the fiscal year ending December 31, 2025. The company achieved total revenue of $427.5 million, a 40% increase from $305.5 million in 2024. This growth was primarily driven by a 38% rise in diagnostic test revenue, which reached $416.7 million, largely due to a 30% increase in test volumes and an 18% increase in average reimbursement rates. The company also noted a rise in other revenue, which increased to $10.9 million from $3.3 million, reflecting contributions from its recently acquired Fabric Genomics segment.
In terms of profitability, GeneDx reported a gross profit of $298.2 million, up 53% from the previous year. However, the company still recorded a net loss of $21.0 million, an improvement from a net loss of $52.3 million in 2024. The reduction in losses was attributed to improved gross margins and operational efficiencies, despite increased expenses in research and development, selling and marketing, and general and administrative costs, which rose by 58%, 31%, and 44%, respectively.
Strategically, GeneDx completed the acquisition of Fabric Genomics in May 2025, which is expected to enhance its capabilities in genomic analysis and interpretation. The acquisition was valued at approximately $36.5 million and is anticipated to contribute to future revenue growth. The company is also focusing on expanding its market presence in pediatric and rare disease diagnostics, leveraging its extensive genomic database, GeneDx Infinity™, which has grown significantly over the years.
Operationally, GeneDx reported a total of 97,271 exome and genome tests resulted in 2025, representing 43% of all test results, compared to 33% in 2024. The company is actively working to increase adoption of its services among healthcare professionals and expand its customer base, particularly in the pediatric outpatient setting. As of December 31, 2025, GeneDx had approximately 1,300 employees, reflecting its growth and expansion efforts.
Looking ahead, GeneDx remains optimistic about its growth trajectory, targeting a nearly $25 billion market opportunity in pediatric and rare diseases, alongside a $20 billion opportunity in adult diseases. The company plans to continue investing in its product development and commercial infrastructure to capitalize on these opportunities, while also addressing the challenges posed by regulatory changes and market competition.
About GeneDx Holdings Corp.
GeneDx Holdings specializes in genetic testing and genomic interpretation for rare and complex diseases. Utilizing exome and whole genome sequencing, the company provides diagnostic solutions, data analysis, and interpretation services to healthcare providers, researchers, and biopharma partners. Its industry-leading dataset and advanced bioinformatics enable accurate, scalable, and actionable genetic insights, primarily serving pediatric and rare disease markets worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.